Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
about
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacologyNovel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimizationCholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application.A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs.PET probes for imaging brain acetylcholinesterase.Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management.Acetylcholinesterase protein level is preserved in the Alzheimer's brain.Immunopurification of Acetylcholinesterase from Red Blood Cells for Detection of Nerve Agent Exposure.Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening.Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.Neuroprotective Effects of the Multitarget Agent AVCRI104P3 in Brain of Middle-Aged Mice
P2860
Q30845482-78C07707-28FA-4C9E-9CB5-946A89F6012CQ33160127-102CCD33-C156-4D4C-A124-9D9982AEDB12Q33715239-1994CB3C-1085-4711-9433-5C0890070F67Q35250966-66296B21-06E6-4A93-BABC-8D8F1406582AQ35840623-FC69A59F-575E-4D5B-9DA8-0D706A2142DBQ36097637-6D06D2E1-6D5F-4280-8A0D-65ADEBF9DA14Q36099648-90A38B20-59E5-4FA8-A4CC-9813B9E4723EQ36475090-D2E0178A-9AA8-4A57-A92E-492502BA10FFQ36632702-8B61FC4D-9B4F-4194-BE03-E2FD6039EB46Q37070395-D40BAB28-4C1F-4E56-8C32-55E01BFA4A06Q37073096-FD4291F9-ACF3-431E-92AE-B8637CA35F52Q37104891-1FD406DF-755F-4849-9F7E-0C1F40317D64Q38166972-2F5A43BE-0EA8-4212-927B-A7ED4B4577A0Q38899961-5AB08134-DDEE-4080-9FCE-2EA3FB861C85Q45310728-20A75956-5129-4316-B343-409483B381BBQ46025102-AE414CC1-5C4C-4702-89B1-3B8D70E333A1Q47111224-08335395-C2DA-4EB6-82DD-4D3F35A10350Q53313228-1B67C140-18D4-4D73-AC7B-60B995A83807Q58764136-F7CEF006-6456-44AB-B7C7-699760D12F40
P2860
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Inhibition of acetylcholineste ...... ents treated with galantamine.
@en
Inhibition of acetylcholineste ...... ents treated with galantamine.
@nl
type
label
Inhibition of acetylcholineste ...... ents treated with galantamine.
@en
Inhibition of acetylcholineste ...... ents treated with galantamine.
@nl
prefLabel
Inhibition of acetylcholineste ...... ents treated with galantamine.
@en
Inhibition of acetylcholineste ...... ents treated with galantamine.
@nl
P2093
P50
P1476
Inhibition of acetylcholineste ...... ents treated with galantamine.
@en
P2093
P304
P356
10.1016/J.NEUROBIOLAGING.2006.09.020
P577
2006-12-29T00:00:00Z